2023-508473-86-00撤回1 期
ExplOratory, Phase 0 Study to assess biodisTribution and PosItron EMission Tomography (PET) Imaging kinetics of [64Cu]Cu-PSMA-R2 in metaStatic prostate cancEr patients
适应症
试验速览
- 阶段
- 1 期
- 状态
- 撤回
- 入组人数
- 6
- 试验地点
- 1
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
Caroline ROUSSEAU
Scientific
Institut De Cancerologie De L Ouest
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
1 期
Deferoxamine, labelled with radioactive Gallium-68, for diagnosis of bacterial infectionspper/lower respiratory tract bacterial infections or orthopaedic bacterial infectionsEUCTR2020-002868-31-ATMedizinische Universität Innsbruck15
进行中（未招募）
1 期
A Phase I/IIa study to evaluate safety and preliminary diagnostic performance of 68Ga-NeoBOMB1 in patients with advanced Tyrosine-kinase inhibitorstreated Gastrointestinal stromal tumours using positron-emission tomography/computer tomography (PET/CT).Gastrointestinal stromal tumours previously or currently under TKI-treatment including at least 50% TKI-resistant patientsEUCTR2016-002053-38-ATMedical University Innsbruck12
进行中（未招募）
1 期
Phase I/IIa study to evaluate 68GaNOTA-anti-MMR-VHH2, a new tracer for positron emission tomografic imaging (PET/CT scan) of macrophages in tumor lesions.Tumour associated macrophages found in tumour lesions of two cancer types: breast cancer or melanomaEUCTR2017-001471-23-BEZ Brussel31
已完成
不适用
Phase I clinical study to evaluate the safety and tolerability of Quadrivalent Influenza Vaccine (QIV) delivered intradermally by a high-density micro-array patch (HD MAP), compared to intramuscular Influvac® Tetra injection, in healthy adults aged 18 to 50 yearsrespiratory infectionRespiratory - Other respiratory disorders / diseasesInfluenzaACTRN12622001203741Vaxxas Pty Ltd150
已完成
不适用
Phase I clinical study to evaluate the safety and tolerability of SARS-CoV-2 spike protein (HexaPro) delivered intradermally by a high-density microarray patch (HD-MAP), in healthy adults aged 18 to 50 years.SARS-CoV-2 infectionInfection - Other infectious diseasesRespiratory - Other respiratory disorders / diseasesACTRN12622000597796Vaxxas Pty Ltd44